[Correspondence] Unadjusted external controls and endpoint selection in Chinese cancer drug trials

I read with interest, the Article by Yichen Zhang and colleagues,1 which presents an important retrospective evaluation of the evidential standards underpinning cancer drug approvals in China between 2017 and 2021. Although the study admirably highlights methodological concerns surrounding trial design and bias, I wish to raise two additional critical methodological shortcomings that warrant further scrutiny.